Being tested
B-cell depletion (anti-CD20): reduce relapses and new lesions in relapsing MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
relapsing MS · B-cell depletion (anti-CD20)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 38
- Running now
- 12
- Controlled phase 2/3 trials
- 11
- People in controlled trials
- 4376
Deciding trials (phase 3): 5 met, 0 did not.
Other linked trials: 33
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2023 · Placebo-controlled · MSFT-NCT05877963
Phase 3 · 2017 · Compared with teriflunomide · MSFT-NCT03277261
Phase 3 · 2017 · Compared with teriflunomide · MSFT-NCT03277248
Phase 3 · 2016 · Compared with dimethyl fumarate, sodium chloride · MSFT-NCT02746744
Three (3%) patients in the rituximab group and 16 (16%) patients in the dimethyl fumarate group had a protocol-defined relapse during the trial, corresponding to a risk ratio of 0·19 (95% CI 0·06-0·62; p=0·0060).
Read by software from the paper's abstractPhase 3 · 2011 · Compared with interferon beta-1a · MSFT-NCT01412333
Phase 3 · 2011 · Compared with interferon beta-1a · MSFT-NCT01247324
Other linked trials: 33
These linked trials do not set the status.
Phase 4 · 2023 · Compared with ocrelizumab
- AMS05Ongoing
Phase 4 · 2023 · Placebo-controlled
- Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaNo result found
Phase 4 · 2022 · Not randomised
- BLOOMSOngoing
Phase 4 · 2022 · Not randomised
- AGNOSNo result found
Phase 4 · 2022 · Not randomised
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabResult in a paper, not read yet
Phase 4 · 2020 · Not randomised
- Short-term B-cell Depletion in Relapsing Multiple SclerosisNo result found
Phase 4 · 2019 · Not randomised
- PRO-MSACTIVEResult in a paper, not read yet
Phase 4 · 2018 · Not randomised
- REFINE-MSOngoing
Phase 3 · 2026 · Not randomised
- CT-P53 3.1Ongoing
Phase 3 · 2024 · Compared with ocrelizumab
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 39 → 38
- 2026-10-27First listed as Being tested
Related hypotheses
- B-cell depletion (anti-CD20): reduce relapses and new lesions in early MS (CIS or RIS)
- B-cell depletion (anti-CD20): prevent attacks in MOGAD
- B-cell depletion (anti-CD20): prevent attacks in NMOSD
- B-cell depletion (anti-CD20): reduce relapses and new lesions in primary progressive MS
- B-cell depletion (anti-CD20): reduce relapses and new lesions in relapsing and progressive MS
- B-cell depletion (anti-CD20): reduce relapses and new lesions in secondary progressive MS
- B-cell depletion (anti-CD20): reduce relapses and new lesions in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error